---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Interleukin-15 receptor agonists"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Interleukin-15 receptor agonists. Topics: FDA-approved indication and mechanism: nogapendekin alfa inbakicept-pmln with BCG; Dosage and administration with BCG; Expanded indication to papillary-only disease by extrapolation, October 2026; QUILT-3.032 Cohort A: design and population; 7 further topics. 11 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/interleukin-15-receptor-agonists"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Interleukin-15 receptor agonists

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Interleukin-15 Receptor Agonists

<a id="topic-2.2.2.1.4-1"></a>

### FDA-approved indication and mechanism: nogapendekin alfa inbakicept-pmln with BCG

> “ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC).”
> “Nogapendekin alfa inbakicept-pmln is an interleukin-15 (IL-15) receptor agonist.”
> “Binding of nogapendekin alfa inbakicept-pmln to its receptor results in proliferation and activation of NK, CD8+, and memory T cells without proliferation of immuno-suppressive Treg cells.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

### Dosage and administration with BCG

> “For induction: ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks.”
> “For maintenance: After BCG and ANKTIVA induction therapy, ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses).”
> “The recommended duration of treatment is until disease persistence after second induction, disease recurrence or progression, unacceptable toxicity, or a maximum of 37 months.”
> “The ANKTIVA in combination with BCG admixture is retained in the bladder for 2 hours and then voided.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

### Expanded indication to papillary-only disease by extrapolation, October 2026

> “On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer.”
> “The current approval expands the indication to include patients with BCG-unresponsive high-grade NMIBC with papillary-only tumors based on review of available scientific information.”
> “Based on the overlapping clinical and non-clinical features of these two histologic types, the FDA concluded that the prior demonstration of efficacy in patients with BCG-unresponsive NMIBC containing CIS could be extrapolated to patients with BCG-unresponsive high-grade papillary disease.”
> “FDA is working toward finalizing the Guidance for Industry, 'Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment' to address this approach.”

Source: [FDA nogapendekin alfa inbakicept-pmln expanded indication notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle)

<a id="topic-2.2.2.1.4-4"></a>

### QUILT-3.032 Cohort A: design and population

> “The efficacy of ANKTIVA in combination with TICE BCG was evaluated in QUILT-3.032 (NCT03022825), a single-arm, multicenter trial in 77 adults with BCG-unresponsive, high-risk, NMIBC with CIS with or without Ta/T1 papillary disease following transurethral resection.”
> “Clinical studies evaluating the efficacy of ANKTIVA in combination with other BCG products have not been conducted.”
> “The major efficacy outcome measures were CR at any time (as defined by negative results for cystoscopy [with TURBT/biopsies as applicable] and urine cytology) and duration of response.”
> “Baseline high-risk NMIBC disease status was 43% refractory and 57% relapsed.”
> “Thirty-one percent (n=24) of patients received a second induction course.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-5"></a>

### QUILT-3.032 Cohort A: efficacy in the prescribing information

| Endpoint | Nogapendekin alfa inbakicept-pmln with TICE BCG |
| --- | --- |
| Participants | “n=77” |
| Complete response rate (95% CI) | “62% (51, 73)” |
| Duration of response, range in months | “0.0, 47.0+” |
| Duration of response ≥12 months, % (n) | “58% (28)” |
| Duration of response ≥24 months, % (n) | “40% (19)” |
| Basis of duration of response | “Based on 48 patients that achieved a complete response at any time” |

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

### QUILT-3.032 Cohort A: long-term follow-up in 100 participants

> “Participants received 400 mcg NAI in combination with 50 mg BCG through intravesical instillation weekly for 6 weeks, with optional reinduction if complete response (CR) was not achieved at month 3.”
> “The CR rate (n = 100) was 71% (95% CI 61.1-79.6) with a median duration of CR of 26.6 months (range 0.03-53.62).”
> “This included 56 participants who responded to the initial induction treatment and 15 participants receiving reinduction treatment.”
> “The Kaplan-Meier estimated cystectomy-free rate in the 71 responders at 24 and 36 months was 90.3% (95% CI 79.7-95.6) and 84.2% (95% CI 69.6-92.1), respectively.”

Source: [Chang et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13657391/)

<a id="topic-2.2.2.1.4-7"></a>

### QUILT-3.032 Cohort B: papillary-only disease

> “NCT03022825 is an open-label, multicenter study of patients with BCG-unresponsive high-grade Ta/T1 papillary nonmuscle-invasive bladder cancer who received 400 μg NAI plus 50 mg BCG intravesically weekly for 6 consecutive weeks.”
> “The primary end point is disease-free survival (DFS) at 12 months.”
> “At July 15, 2024, data cutoff, the DFS rates at 12, 24, and 36 months were 58.2% (95% CI: 46.6, 68.2), 52.1% (95% CI: 40.3, 62.7), and 38.2% (95% CI: 25.6, 50.6), respectively.”
> “Cystectomy avoidance rates at 12 and 36 months were 92.2% (95% CI: 83.4, 96.4) and 81.8% (95% CI: 68.1, 90.1), with median time to cystectomy not reached.”

Source: [Chang et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12708036/)

<a id="topic-2.2.2.1.4-8"></a>

### European guideline summary of QUILT-3.032

> “The QUILT 3.032 trial has evaluated the potential of the IL-15 superagonist nagopendekin alfa-inbakicept (NAI), administered intravesically in combination with BCG, in BCG-unresponsive HG NMIBC, demonstrating 3-, 6- and 12-month CRR of 55%, 56% and 45%, respectively, in patients with CIS (n = 82), with a median duration of 26.6 months.”
> “Among patients with Ta/T1 disease (n = 72), the 12-month estimated DFS rate was 55.4%, with median DFS of 19.3 months.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.4-9"></a>

### FDA review: contribution of each component of the combination

> “Cohort C (N-803 as a single agent) was closed early due to futility based on 10 patients; CRR was 20% [95% CI: 3, 56] with only 1 patient with a durable CR ≥ 6 months.”
> “The CRR with BCG was 14% [95% CI: 2, 43], indicating that the response rate observed with the combination of N-803 and BCG did not appear to be due solely to the activity of BCG.”
> “TICE BCG was the only strain studied in QUILT-3.032 and is currently the only approved BCG strain marketed in the U.S.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

<a id="topic-2.2.2.1.4-10"></a>

### Safety in QUILT-3.032 Cohort A

> “Serious adverse reactions occurred in 16% of patients receiving ANKTIVA with TICE BCG.”
> “A fatal adverse reaction of cardiac arrest occurred in 1 (1.1%) patient receiving ANKTIVA with TICE BCG.”
> “Permanent discontinuation of ANKTIVA with TICE BCG due to adverse reactions occurred in 7% of patients.”
> “The most common (≥15%) adverse reactions, including laboratory test abnormalities, were increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.1.4-11"></a>

### Progression to muscle-invasive disease and delayed cystectomy

> “Delaying cystectomy in patients with BCG-unresponsive NMIBC could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal.”
> “10% (n = 8) progressed to muscle invasive (T2 or greater) bladder cancer, including 7 during the treatment period.”
> “The median time between determination of persistent or recurrent CIS and progression to muscle-invasive disease was 107 days (range: 0 – 210).”
> “If patients with BCG-unresponsive NMIBC have evidence of high-grade disease after a second induction course of ANKTIVA with BCG, reconsider cystectomy.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
